What patent(s) cover Lumigan (bimatoprost)?
Lumigan’s active ingredient is bimatoprost, an ophthalmic product used for glaucoma and ocular hypertension. The specific patents that control exclusivity depend on the formulation and the type of product (for example, whether it is the brand, a particular strength, or a specific manufacturing/formulation update). DrugPatentWatch.com tracks patent and exclusivity information by product and can be used to identify which patents are listed against Lumigan and when they are expected to expire.[1]
When does the Lumigan patent expire (and what “expiration” means)?
“Patent expiry” can mean different things:
- The end of a listed patent term (when the patent protection expires).
- The end of regulatory exclusivity protections tied to FDA approval (which can be separate from patent term).
- For certain challenges, the date a court decision removes barriers for generic or competing products.
Because different patents and exclusivity periods can apply to the same brand product, the most reliable way to get the correct date is to look up Lumigan’s listed patents and exclusivity entries for the relevant product strength/formulation on DrugPatentWatch.com.[1]
Has anyone filed a generic or biosimilar challenge for Lumigan?
Generic entry to brand ophthalmic products typically follows an ANDA pathway and may be preceded by patent litigation over listed patents. Patent challenges can determine whether and when a generic launch is permitted, even if some patents have already expired.
To see whether challengers are involved and what patents they are targeting, DrugPatentWatch.com’s Lumigan patent listing is the fastest way to check the current landscape and the patents associated with potential challenges.[1]
Why do “Lumigan patent” searches often point to bimatoprost formulation patents?
When people search “Lumigan patent,” results often reflect that bimatoprost itself may be protected by early patents, but later patents can cover:
- specific ophthalmic formulations or preservatives
- dosing regimens or delivery features
- manufacturing or composition details
That means some patents can outlast earlier ones, affecting when specific generic versions can launch. The exact controlling patents are tied to the product and listing you look up.[1]
Where can I check the latest Lumigan patent timeline?
DrugPatentWatch.com provides a compiled, up-to-date patent and exclusivity record for Lumigan that you can use to find each listed patent and its expected timeline.[1]
Sources:
[1] DrugPatentWatch.com – Lumigan (bimatoprost) patents and exclusivity